Suven Pharmaceuticals Ltd Environmental Analytics
Environmental and financial analysis dashboard for Suven Pharmaceuticals Ltd. Industry: MANUFACTURING
Company Overview for Suven Pharmaceuticals Ltd
Highlights
Showing data for FY2023
Operational Environmental Cost
$15m
Operational Environmental Cost Intensity
12%
Total Environmental Cost
$28m
Total Environmental Cost Intensity
22%
ΔOperational Environmental Cost (2020-2023)
$2.65m
Decoupling Rate (2020-2023)
-9.72%
Adjusted EBITDA
N/A
Adjusted EBITDA Margin
N/A
Environmental cost statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| OPERATIONAL SOCIAL COST OF CARBON | ||||
| 30.33% | 11.29% | -10.14% | ||
| 5.41% | 5.59% | 6.64% | 7.72% | |
| 35.06% | 3.45% | -23.38% | ||
| 3.90% | 4.17% | 4.61% | 4.57% | |
| $13m | $17m | $18m | $15m | |
| 32.31% | 7.94% | -15.57% | ||
| 9.31% | 9.76% | 11.26% | 12.29% | |
| INDIRECT SOCIAL COST OF CARBON | ||||
| N/A | N/A | 9938.25% | ||
| N/A | N/A | 0.08% | 9.85% | |
| N/A | N/A | 51.09% | ||
| N/A | N/A | 11.33% | 22.15% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. Scope 2: Social Cost of Carbon is calculated using market-based emissions data. | ||||
Environmental cost bridge
Showing data for FY2023
Integrated financial analysis
Highlights
Showing data for FY2023
Adjusted EBITDA Margin
N/A
Adjusted EBIT Margin
N/A
EV / Adjusted EBITDA
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
EV / Adjusted EBIT
Company Value: Placeholder
Industry Average: Placeholder
Coming soon
Integrated income statement
Showing data for FY2023
| USD MM | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| INCOME STATEMENT | ||||
$138m | $174m | $163m | $126m | |
| 26.16% | -6.39% | -22.71% | ||
N/A | N/A | N/A | N/A | |
| 0.00% | 0.00% | 0.00% | 0.00% | |
N/A | N/A | N/A | N/A | |
| 0.00% | 0.00% | 0.00% | 0.00% | |
N/A | N/A | N/A | N/A | |
| 0.00% | 0.00% | 0.00% | 0.00% | |
| ENVIRONMENTAL COST DATA | ||||
$13m | $17m | $18m | $15m | |
| 9.31% | 9.76% | 11.26% | 12.29% | |
| FINANCIAL DATA ADJUSTED FOR OPERATIONAL ENVIRONMENTAL COST | ||||
N/A | N/A | N/A | N/A | |
| 0.00% | 0.00% | 0.00% | 0.00% | |
N/A | N/A | N/A | N/A | |
| 0.00% | 0.00% | 0.00% | 0.00% | |
All figures are denominated in millions of USD. USD is the base currency used to monetize, other currency equivalents are calculated using end of year exchange rates. | ||||
Environmental EBITDA bridge
Showing data for FY2023
Industry benchmark
MANUFACTURE OF PHARMACEUTICAL PREPARATIONS
Scope 1 (% of Sales)
7.72%
Scope 2 (% of Sales)
4.57%
Operational Environmental Cost Intensity
12%
Scope 3 (% of Sales)
9.85%
Total Environmental Cost Intensity
22%
Selected peer group
Showing data for FY2023
NAME | COUNTRY | OPERATIONAL ENV. COST | OPERATIONAL ENV. COST INTENSITY |
|---|---|---|---|
Suven Pharmaceuticals Ltd | IN | $15m | 12.29% |
Loading similar companies data...
Industry distribution
Showing data for FY2023
Note: Outliers are calculated using the 1.5 * IQR method, where values outside Q1 - 1.5 * IQR and Q3 + 1.5 * IQR are considered outliers.
Estimated Social Cost of Carbon Scope 3 breakdown
Percentage breakdown of Social Cost of Carbon Scope 3 into various categories
Showing data for FY2023
SCOPE 3 CATEGORY | Company (USD) | Company % | Industry Avg (USD) | Industry Avg % |
|---|---|---|---|---|
Purchased goods (1 & 2) | $3m | 37.18% | N/A | N/A |
Energy-related activities (3) | $3m | 35.68% | N/A | N/A |
Upstream transportation (4) | $1m | 5.52% | N/A | N/A |
Waste (5) | $0m | 0.84% | N/A | N/A |
Business travel (6) | $0m | 0.52% | N/A | N/A |
Commuting (7) | $0m | 0.41% | N/A | N/A |
Upstream leased assets (8) | N/A | N/A | N/A | N/A |
Downstream transportation (9) | $1m | 5.43% | N/A | N/A |
Processing of products (10) | $0m | 0.02% | N/A | N/A |
Use of products (11) | N/A | N/A | N/A | N/A |
Final treatment of products (12) | $1m | 14.40% | N/A | N/A |
Downstream leased assets (13) | N/A | N/A | N/A | N/A |
Franchises (14) | N/A | N/A | N/A | N/A |
Investments (15) | N/A | N/A | N/A | N/A |
Total | $9m | 100.00% | $0m | 100.00% |
Scope 3 breakdown visualization
Showing data for FY2023